Deepinder Goyal’s ₹85,000 Temple wearable is facing scrutiny over its price and scientific credibility. Business Standard highlights the controversy, while The Economic Times reports that doctors are questioning its claims. For an Indian startup targeting international buyers, credibility matters alongside ambition. [1][5]
Global ambitions, disputed claims
The Times of India reported on 9 November that Goyal said the company had made no medical claim. On 10 November, Livemint reported his position that Temple was designed for the world and that he did not expect India to account for more than 1% of sales. That is his expectation, not a reported sales outcome. [7][3]
These leads establish a disagreement. They do not provide the underlying studies, a complete account of the doctors’ objections or enough product detail to assess performance. A high price alone neither validates nor disproves a device’s usefulness.
Capability needs credibility
Sanatan Daily’s assessment is that Indian innovation need not be confined to the domestic market. But international ambition should be matched by clear explanations of what a product measures, what evidence supports it and what buyers should not infer.
The constructive next step is transparent evidence and precise product communication. That would serve consumers while strengthening confidence in Indian technological capability.

